UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2016
Flexion Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36287 |
|
26-1388364 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
10 Mall Road, Suite 301 Burlington, Massachusetts |
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (781) 305-7777
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Flexion Therapeutics, Inc. (“Flexion”) held its 2016 Annual Meeting of Stockholders (the “Annual Meeting”) on June 15, 2016. At the Annual Meeting, Flexion’s stockholders (i) elected two directors to serve on Flexion’s Board of Directors (the “Board”) until Flexion’s 2019 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, until their death, resignation or removal, and (ii) ratified the selection of PricewaterhouseCoopers LLP as Flexion’s independent registered public accounting firm for fiscal year 2016. There were 21,570,395 outstanding shares eligible to vote as of April 19, 2016, the record date for the Annual Meeting.
The directors elected to the Board, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below:
|
Director |
|
For |
|
|
Withheld |
|
|
Broker Non-Votes |
|
|||
|
Scott A. Canute |
|
|
12,220,478 |
|
|
|
3,186,875 |
|
|
|
4,582,090 |
|
|
Samuel D. Colella |
|
|
13,620,392 |
|
|
|
1,786,961 |
|
|
|
4,582,090 |
|
The proposal to ratify the selection of PricewaterhouseCoopers LLP as Flexion’s independent registered public accounting firm for fiscal year 2016 received the following votes:
|
For |
|
|
Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
||||
|
|
19,983,629 |
|
|
|
3,301 |
|
|
|
2,513 |
|
|
|
— |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
Flexion Therapeutics, Inc. |
||
|
|
|
||||
|
|
|
|
|
||
|
Dated: June 16, 2016 |
|
|
By: |
|
/s/ Frederick W. Driscoll |
|
|
|
|
|
|
Frederick W. Driscoll |
|
|
|
|
|
|
Chief Financial Officer |